loading...| Preferred Name |
Zotiraciclib Citrate |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105851 |
| CAS_Registry |
1204918-73-9 |
| code |
C105851 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 |
| Contributing_Source |
CTRP GDC FDA |
| DEFINITION |
An orally bioavailable citrate salt form of zotiraciclib a multi-kinase inhibitor for cyclin dependent kinase (CDK) subtypes 1, 2, 7 and 9, Janus-associated kinase 2 (JAK2), FMS-related tyrosine kinase 3 (FLT3, FLK2, STK1), with potential antineoplastic activity. Upon oral administration, CDK/JAK2/FLT3 Inhibitor TG02 binds to and inhibits the CDK subtypes, JAK2, and FLT3. TG02 also inhibits, to a lesser extent, TYK2, TYRO3, STAT5 and P38delta. This may result in both an induction of apoptosis and an inhibition of tumor cell proliferation in cancer cells that overexpress these kinases. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival. CDKs are serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias. |
| Display_Name |
Zotiraciclib Citrate |
| FDA_UNII_Code |
3VF50SU4RZ |
| FULL_SYN |
TG02 Citrate ZOTIRACICLIB CITRATE 20-Oxa-5,7,14,27-tetraazatetracyclo(19.3.1.12,6.18,12)heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 14-Methyl-, 2-Hydroxy-1,2,3-propanetricarboxylate (1:1) Zotiraciclib Citrate SB1317 Citrate |
| Has_Target |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126982 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C89769 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C28494 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C25842 |
| Is_Value_For_GDC_Property | |
| label |
Zotiraciclib Citrate |
| Maps_To |
CDK/JAK2/FLT3 Inhibitor TG02 Citrate Zotiraciclib Citrate |
| NCI_Drug_Dictionary_ID |
686272 |
| NCI_META_CUI |
CL447179 |
| PDQ_Closed_Trial_Search_ID |
686272 |
| PDQ_Open_Trial_Search_ID |
686272 |
| Preferred_Name |
Zotiraciclib Citrate |
| prefixIRI |
Thesaurus:C105851 |
| prefLabel |
Zotiraciclib Citrate |
| Semantic_Type |
Pharmacologic Substance |
| subClassOf |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| There are currently no mappings for this class. | |||